These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 29677483)

  • 21. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
    Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
    Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
    Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
    Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
    Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
    Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
    Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition.
    El-Dash Y; Elzayat E; Abdou AM; Hassan RA
    Bioorg Chem; 2021 Sep; 114():105137. PubMed ID: 34237644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
    Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
    Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
    Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
    Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
    El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
    Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and preclinical evaluation of 5-methyl-N
    Devambatla RKV; Choudhary S; Ihnat M; Hamel E; Mooberry SL; Gangjee A
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3085-3093. PubMed ID: 30098869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
    Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect.
    Sana S; Reddy VG; Bhandari S; Reddy TS; Tokala R; Sakla AP; Bhargava SK; Shankaraiah N
    Eur J Med Chem; 2020 Aug; 200():112457. PubMed ID: 32422489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
    Salerno S; García-Argáez AN; Barresi E; Taliani S; Simorini F; La Motta C; Amendola G; Tomassi S; Cosconati S; Novellino E; Da Settimo F; Marini AM; Via LD
    Eur J Med Chem; 2018 Apr; 150():446-456. PubMed ID: 29547832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
    Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
    Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity.
    Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A
    Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
    Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of novel furan, furo[2,3-d]pyrimidine and furo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as potential VEGFR-2 inhibitors.
    Abd El-Mageed MMA; Eissa AAM; Farag AE; Osman EEA
    Bioorg Chem; 2021 Nov; 116():105336. PubMed ID: 34530235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
    Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.